18F氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描与头颈癌：患者管理与预后
18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes.
作者信息
Sheikhbahaei Sara, Marcus Charles, Subramaniam Rathan M
机构信息
Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA.
Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 601 North Caroline Street, Baltimore, MD, USA; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, 624 North Broadway, Baltimore, MD 21205, USA.
出版信息
PET Clin. 2015 Apr;10(2):125-45. doi: 10.1016/j.cpet.2014.12.001. Epub 2015 Feb 20.
There is a growing body of evidence that point to the value of 18F fluoro-deoxyglucose-PET/CT in the management of head and neck cancer (HNC) patients and predicting patient-related outcomes. FDG-PET/CT changes the baseline staging (compared with CT or MR imaging), guides appropriate therapy selection, separates the responders and non-responders for therapy assessment, adds value to clinical assessment in follow-up, and predicts patient survival outcomes. FDG-PET/CT can identify the recurrences in earlier stages and individualize follow-up regimens in HNC patients. This article reviews the value of FDG-PET/CT in management strategy and survival outcome of HNC patients.
越来越多的证据表明，18F氟脱氧葡萄糖-PET/CT在头颈部癌（HNC）患者的管理及预测患者相关预后方面具有重要价值。FDG-PET/CT改变了基线分期（与CT或磁共振成像相比），指导合适的治疗选择，区分治疗评估中的反应者和无反应者，为随访中的临床评估增加价值，并预测患者的生存结果。FDG-PET/CT能够在早期识别复发情况，并使HNC患者的随访方案个体化。本文综述了FDG-PET/CT在HNC患者管理策略和生存结果方面的价值。
Zotero 插件